Limaca Medical is developing KORA, an electro-mechanically driven endoscopic ultrasound-guided biopsy product for improved diagnosis of gastrointestinal system tumors.

KORA obtains higher-quality core tissue for superior histopathologic analysis, improved diagnostic accuracy, and better clinical outcomes.The companys initial focus will be on pancreatic tumors.

Future markets in Limacas pipeline include liver and lung cancer.Limaca Medical is a Trendlines incubator company.In May 2022, the companys Precision-GI received Breakthrough Device designation from the FDA.